Journal of Neuro-Oncology

, Volume 51, Issue 1, pp 41–45

Thalidomide as an Anti-angiogenic Agent in Relapsed Gliomas

  • S.C. Short
  • D. Traish
  • A. Dowe
  • F. Hines
  • M. Gore
  • M. Brada
Article

Abstract

Background. Thalidomide (α-phthalimidoglutarimide), a synthetic sedative drug, has anti-angiogenic properties due to inhibition of growth-factor mediated neovascularisation and has been shown to inhibit tumour growth in experimental solid tumour models.

Aim. To assess response of recurrent malignant gliomas to thalidomide.

Methods. Eighteen patients with recurrent gliomas were enrolled to an open, non-randomised phase II trial between October 1997 and December 1999. All patients had failed following treatment with radiotherapy and chemotherapy with PCV and/or temozolomide regimens. Eleven patients had high-grade gliomas de novo and 7 high-grade gliomas following transformation of low-grade gliomas. Thalidomide was prescribed at 100 mg/day p.o. continuously. Response was assessed at 4-weekly intervals. Disease progression was defined as neurological deterioration and/or radiological evidence of increased tumour size. Treatment was discontinued at the time of disease progression, or if toxicity occurred, or at patients' request.

Results. Thalidomide was prescribed for a median of 42 days (range 7–244). Treatment was discontinued due to toxicity (peripheral sensory neuropathy) in 1 patient. Six patients died before response could be fully assessed and are classified as non-responders. Of 12 who continued treatment for more than 4 weeks, 1 patient had clinical and radiological response (PR), 2 patients had stable disease for 2 and 4 months respectively and 9 patients had disease progression. The median survival from the start of thalidomide was 2.5 months.

Conclusion. The efficacy of thalidomide in terms of response in recurrent gliomas is low, with a partial response rate of only 6%. Future studies should investigate thalidomide in combination with other agents and at an earlier stage of disease. Methods to assess anti-angiogenic properties such as changes in tumour vasculature could be employed as initial surrogate end-points in the investigation of efficacy.

thalidomide glioma anti-angiogenesis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27–31, 1995Google Scholar
  2. 2.
    Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58–61, 1989Google Scholar
  3. 3.
    Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 3: 65–71, 1992Google Scholar
  4. 4.
    Goto F, Goto K, Weindel K, Folkman J: Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels [see comments]. Lab Invest 69: 508–517, 1993Google Scholar
  5. 5.
    Bloemendal HJ, Logtenberg T, Voest EE: New strategies in anti-vascular cancer therapy [see comments]. Eur J Clin Invest 29: 802–809, 1999Google Scholar
  6. 6.
    Giavazzi R, Giulia T: Angiogenesis and angiogenesis inhibitors in cancer. Forum (Genova) 9: 261–272, 1999Google Scholar
  7. 7.
    Carroll RS, Zhang J, Bello L, Melnick MB, Maruyama T, Mc LBP: KDR activation in astrocytic neoplasms. Cancer 86: 1335–1341, 1999Google Scholar
  8. 8.
    Li VW, Folkerth RD, Watanabe H, Yu C, Rupnick M, Barnes P, Scott RM, Black PM, Sallan SE, Folkman J: Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 344: 82–86, 1994Google Scholar
  9. 9.
    Plate KH, Breier G, Farrell CL, Risau W: Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Invest 67: 529–534, 1992Google Scholar
  10. 10.
    Jensen RL: Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol 49: 189–195; discussion 196, 1998Google Scholar
  11. 11.
    D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Nat Acad Sci USA 91: 4082–4085, 1994Google Scholar
  12. 12.
    Minchinton AI, Fryer KH, Wendt KR, Clow KA, Hayes MM: The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 7: 339–343, 1996Google Scholar
  13. 13.
    Verheul HM, Panigrahy D, Yuan J, D'Amato RJ: Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. British J Cancer 79: 114–118, 1999Google Scholar
  14. 14.
    Bauer KS, Dixon SC, Figg WD: Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55: 1827–1834, 1998Google Scholar
  15. 15.
    Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S: Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 32: 866–869, 1995Google Scholar
  16. 16.
    Crawford CL: Use of thalidomide in leprosy. Adverse Drug React Toxicol Rev 13: 177–192, 1994Google Scholar
  17. 17.
    Tramontana JM, Utaipat U, Molloy A, Akarasewi P, Burroughs M, Makonkawkeyoon S, Johnson B, Klausner JD, Rom W, Kaplan G: Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1: 384–397, 1995Google Scholar
  18. 18.
    Macdonald DR, Cascino TL, Schold SC, Cairncross JG: Response criteria for phase II studies of supratentorial gliomas. J Clin Oncol 8: 1277–1280, 1990Google Scholar
  19. 19.
    Avgeropoulos NG, Batchelor TT: New treatment strategies for malignant gliomas. Oncologist 4: 209–224, 1999Google Scholar
  20. 20.
    Lund EL, Spang-Thomsen M, Skovgaard-Poulsen H, Kristjansen PE: Tumor angiogenesis – a newtherapeutic target in gliomas. Acta Neurol Scand 97: 52–62, 1998Google Scholar
  21. 21.
    Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B: Antitumor activity of thalidomide in refractory multiple myeloma [see comments]. New England J Med 341: 1565–1571, 1999Google Scholar
  22. 22.
    Auerbach R, Arensman R, Kubai L, Folkman J: Tumorinduced angiogenesis: lack of inhibition by irradiation. Int J Cancer 15: 241–245, 1975Google Scholar
  23. 23.
    Fine HA, Figg W, Jaeckle K et al.: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18: 708–715, 2000Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • S.C. Short
    • 1
  • D. Traish
    • 1
  • A. Dowe
    • 1
  • F. Hines
    • 1
  • M. Gore
    • 1
  • M. Brada
    • 1
  1. 1.Unit of Neuro-Oncology and Academic Unit of Radiotherapy and OncologyThe Institute of Cancer Research and The Royal Marsden NHS TrustSutton, SurreyUK

Personalised recommendations